VYNDAQEL, also known by its generic name tafamidis, is a medication primarily used in the treatment of transthyretin-mediated amyloidosis (ATTR) in adults. This condition is characterized by the accumulation of abnormal amyloid proteins in the body, which can lead to various organ dysfunctions, particularly affecting the heart and nervous system. VYNDAQEL works by stabilizing the transthyretin protein, preventing it from misfolding and aggregating into amyloid fibrils, thereby slowing the progression of the disease. It is an oral medication, making it a convenient option for patients. Approved by regulatory agencies in several countries, VYNDAQEL represents a significant advancement in the management of ATTR, offering hope to patients with this rare and previously difficult-to-treat condition.